You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 8, August 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Small Case Series
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Infectious Diseases, Other
 •Choroidal Neovascularization
 •Pediatric Ophthalmology
 •Retinal/ Chorioretinal Disorders
 •Pediatrics
 •Pediatrics, Other
 •Drug Therapy
 •Drug Therapy, Other
 •Infectious Diseases
 •Alert me on articles by topic

Toxoplasmosis-Associated Neovascular Lesions Treated Successfully With Ranibizumab and Antiparasitic Therapy

Joseph D. Benevento, MD; Rama D. Jager, MD, MBA; A. Gwendolyn Noble, MD, PhD; Paul Latkany, MD; William F. Mieler, MD; Mari Sautter, BA; Sanford Meyers, MD; Marilyn Mets, MD; Michael A. Grassi, MD; Peter Rabiah, MD; Kenneth Boyer, MD; Charles Swisher, MD; Rima McLeod, MD; for the Toxoplasmosis Study Group

Arch Ophthalmol. 2008;126(8):1152-1156.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Choroidal neovascular membranes (CNVMs) rarely complicate toxoplasmic chorioretinitis1-5 and are managed by observation; antiparasitic, anti-inflammatory medication; laser photocoagulation; surgical excision; or photodynamic therapy, with variable outcomes. As occurs with CNVMs secondary to age-related macular degeneration, Toxoplasma gondii increases expression of hypoxia-inducible factor–1{alpha} in tissue cultures along with vascular endothelial growth factor (VEGF).6

Report of Cases

Two patients with prior ocular toxoplasmosis had active CNVMs with subretinal blood and fluid on clinical examination and ocular coherence tomography (OCT) and hyperfluorescence with leakage documented on fluorescein angiogram (FA). Each was treated with off-label intravitreal injections of ranibizumab (Genentech, Inc, South San Francisco, California) and . . . [Full Text of this Article]

Case 1

Case 2


Comment

AUTHOR INFORMATION






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.